HeartBeam Reorganizes to Accelerate Global Commercialization of Cardiac Monitoring Technology

HeartBeam Inc. (NASDAQ: BEAT) has announced a strategic reorganization aimed at accelerating the execution of its commercialization strategy for its cardiac monitoring technology. The company, which focuses on transforming the detection and monitoring of critical cardiac conditions, said the new structure is designed to expand its global market reach, improve capital efficiency, and streamline decision-making.

Under the reorganization, founder and president Branislav Vajdic, Ph.D., and executive chairman Rich Ferrari will lead focused implementation teams. The company said this structure is intended to improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.

HeartBeam’s strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels. The company plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies. This builds on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The company also aims to advance development beyond arrhythmia assessment toward heart attack detection.

HeartBeam’s technology is designed to be the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a 12-lead ECG. The platform is intended for portable devices that can be used wherever the patient is, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.

The company holds over 20 issued patents related to its technology. In December 2024, HeartBeam received FDA clearance for its 3D ECG technology for arrhythmia assessment, followed by clearance for the 12-lead ECG synthesis software in December 2025. Details on the intended use of its technology are available at HeartBeam’s indications page.

The reorganization is expected to help HeartBeam better execute on its commercialization strategy and improve capital efficiency as it seeks to bring its cardiac monitoring technology to a global market. The company’s focus on heart attack detection represents a significant expansion beyond its current arrhythmia assessment capabilities.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is HeartBeam Reorganizes to Accelerate Global Commercialization of Cardiac Monitoring Technology.

The post HeartBeam Reorganizes to Accelerate Global Commercialization of Cardiac Monitoring Technology appeared first on citybuzz.